abstract |
The present invention relates to methods of inhibiting the activity of human kallikrein 7 (KLK7) (also known as the serine protease keratinocyte chymotrypsin, SCCE). The present invention further relates to the use of KLK7 inhibitors of formula I for the prevention and treatment of diseases, more particularly for the treatment and prevention of skin diseases. The present invention also provides novel compounds that have been shown to be KLK7 inhibitors. |